Arthritis biosimilar gets PBS listing

Inflectra has become the first of the so-called “mAb” biosimilars to be added to the Pharmaceutical Benefits Scheme, its maker Pfizer has announced.

The infliximab biosimilar is approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, as well as both adult and paediatric Crohn’s disease and ulcerative colitis.

The listing follows a PBAC recommendation